STERIS plc STE Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0001757898-25-000005
cik 1757898
name STERIS PLC
sic 3842
countryba IE
stprba
cityba DUBLIN
zipba 2
bas1 70 SIR JOHN ROGERSON'S QUAY
bas2
baph 35312322000
countryma IE
stprma
cityma DUBLIN
zipma 2
mas1 70 SIR JOHN ROGERSON'S QUAY
mas2
countryinc IE
stprinc
ein 000000000
former STERIS LTD
changed 20181101
afs 1-LAF
wksi 1
fye 0331
form 10-K
period 20250331
fy 2024
fp FY
filed 20250529
accepted 2025-05-29 16:37:00.0
prevrpt 0
detail 1
instance ste-20250331_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001757898-25-000005 20240331 Accrued Liabilities Current 319744000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Accrued Income Taxes Current 21456000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Accumulated Other Comprehensive Income Loss Net Of Tax -292338000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Amortization Of Inventory Fair Value Adjustments 4822000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20240331 Assets 3203217000.0000 USD 0 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20240331 Assets 10258793000.0000 USD 0 us-gaap/2024 Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20240331 Assets Current 2869123000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Commitments And Contingencies 127396000.0000 USD 0 us-gaap/2024 Purchase Commitment Excluding Longterm Commitment= Commercial Commitments;
0001757898-25-000005 20240331 Common Stock Value 4543176000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Cost Of Goods And Services Sold 1284177000.0000 USD 4 us-gaap/2024 Product Or Service= Service;
0001757898-25-000005 20250331 Cost Of Goods And Services Sold 1542476000.0000 USD 4 us-gaap/2024 Product Or Service= Service;
0001757898-25-000005 20240331 Depreciation Depletion And Amortization 127823000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20250331 Depreciation Depletion And Amortization 142003000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20230331 Dividends Common Stock Cash 183498000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20230331 Earnings Per Share Basic 1.0700 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Earnings Per Share Basic 3.8300 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Gain Loss On Disposition Of Business And Equity Investments Net -6444000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20240331 Gain Loss On Sale Of Business And Equity Investments Continuing Operations 0.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20230331 Goodwill 3879219000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Goodwill 181812000.0000 USD 0 us-gaap/2024 Reporting Unit= Life Sciences;
0001757898-25-000005 20240331 Goodwill 2500910000.0000 USD 0 us-gaap/2024 Reporting Unit= Health Care;
0001757898-25-000005 20250331 Goodwill 170928000.0000 USD 0 us-gaap/2024 Reporting Unit= Life Sciences;
0001757898-25-000005 20230331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity -450384000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Increase Decrease In Accounts Payable 53342000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Increase Decrease In Noncontrolling Interests Other 64000.0000 USD 4 0001757898-25-000005 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets 1552000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Intangible Assets Net Excluding Goodwill 2119282000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Long Term Debt Noncurrent 3120162000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Long Term Debt Noncurrent 1918701000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Loss On Classification As Held For Sale 0.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20240331 Net Cash Provided By Used In Financing Activities -85186000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Net Cash Provided By Used In Investing Activities -383330000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Net Cash Provided By Used In Investing Activities 388773000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Net Income Loss 614641000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Net Income Loss Attributable To Noncontrolling Interest 1433000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Noncontrolling Interest Increase From Contributions To Noncontrolling Interest Holders 2994000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20250331 Operating Expenses 1536123000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Operating Lease Liability Noncurrent 145828000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Operating Lease Right Of Use Asset 173201000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Operating Lease Right Of Use Asset 4571000.0000 USD 0 us-gaap/2024 Business Acquisition= Series Of Individually Immaterial Business Acquisitions;
0001757898-25-000005 20250331 Other Assets Noncurrent 83046000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Payments Of Financing Costs 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Payments To Acquire Investments 10750000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Proceeds From Divestiture Of Businesses 814558000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Property Plant And Equipment Net 1765180000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Property Plant And Equipment Net 1009979000.0000 USD 0 us-gaap/2024 Geographical= U S;
0001757898-25-000005 20250331 Property Plant And Equipment Net 872931000.0000 USD 0 us-gaap/2024 Geographical= Other Foreign Entities Member;
0001757898-25-000005 20230331 Repayments Of Term Loans 156875000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20230331 Restructuring Costs 485000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Restructuring Costs 26045000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Revenues 3085131000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Revenues 148170000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Product Or Service= Servicerevenues;
0001757898-25-000005 20230331 Revenues 74292000.0000 USD 4 us-gaap/2024 Geographical= I E;
0001757898-25-000005 20230331 Revenues 3254373000.0000 USD 4 us-gaap/2024 Geographical= U S;
0001757898-25-000005 20230331 Revenues 2363754000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001757898-25-000005 20230331 Revenues 2172512000.0000 USD 4 us-gaap/2024 Product Or Service= Service;
0001757898-25-000005 20240331 Revenues 1273058000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment; Product Or Service= Servicerevenues;
0001757898-25-000005 20240331 Revenues 164602000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Product Or Service= Servicerevenues;
0001757898-25-000005 20240331 Revenues 2374747000.0000 USD 4 us-gaap/2024 Product Or Service= Service;
0001757898-25-000005 20250331 Revenues 1038573000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies;
0001757898-25-000005 20250331 Revenues 542271000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member;
0001757898-25-000005 20250331 Revenues 1344572000.0000 USD 4 us-gaap/2024 Geographical= Otherforeignlocations;
0001757898-25-000005 20240331 Selling General And Administrative Expense 58218000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Consolidation Items= Operating Segments;
0001757898-25-000005 20250331 Selling General And Administrative Expense 1334276000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Selling General And Administrative Expense 52485000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Share Based Compensation 38951000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Stockholders Equity 6603405000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 6544637000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 1911533000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 6315346000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 6615757000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4420413000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20250331 Stock Issued During Period Shares Employee Stock Purchase Plans 420000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Accounts Payable Current 251723000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Amortization Of Inventory Fair Value Adjustments 7363000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20250331 Assets 10146811000.0000 USD 0 us-gaap/2024 Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -1337000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Commitments And Contingencies 77927000.0000 USD 0 us-gaap/2024 Purchase Commitment Excluding Longterm Commitment= Longterm Construction Contracts Member;
0001757898-25-000005 20250331 Common Stock Shares Issued 98301000.0000 shares 0 us-gaap/2024
0001757898-25-000005 20250331 Earnings Per Share Diluted 6.2000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Employee Related Liabilities Current 164831000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Goodwill 4070712000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Goodwill Impairment Loss 441643000.0000 USD 4 us-gaap/2024 Geographical= U S;
0001757898-25-000005 20230331 Income Loss From Continuing Operations Per Basic Share 5.5900 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Income Loss From Discontinued Operations Net Of Tax Per Basic Share -4.5200 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Interest Expense Nonoperating 86261000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 794000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20230331 Net Cash Provided By Used In Operating Activities 756947000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Operating Lease Right Of Use Asset 667000.0000 USD 0 us-gaap/2024 Business Acquisition= Series Of Individually Immaterial Business Acquisitions;
0001757898-25-000005 20240331 Operating Lease Right Of Use Asset 0.0000 USD 0 us-gaap/2024 Business Acquisition= Series Of Individually Immaterial Business Acquisitions;
0001757898-25-000005 20250331 Operating Lease Right Of Use Asset 1737000.0000 USD 0 us-gaap/2024 Business Acquisition= B D Acquisition;
0001757898-25-000005 20230331 Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax -1264000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax -7211000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest -36319000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001757898-25-000005 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 109638000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001757898-25-000005 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -149000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001757898-25-000005 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -36170000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001757898-25-000005 20240331 Other Liabilities Noncurrent 71546000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Other Prepaid Expense Current 174349000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Payments For Repurchase Of Common Stock 11765000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Payments Of Dividends Common Stock 219875000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Payments Of Merger Related Costs Financing Activities 6242000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Payments To Acquire Property Plant And Equipment 361969000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Proceeds From Divestiture Of Businesses 5228000.0000 USD 4 us-gaap/2024 Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Animal Health Divestiture;
0001757898-25-000005 20230331 Profit Loss 107030000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20240331 Property Plant And Equipment Net 686598000.0000 USD 0 us-gaap/2024 Geographical= Other Foreign Entities Member;
0001757898-25-000005 20230331 Research And Development Expense 98477000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Research And Development Expense 8255000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Revenues 896590000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment; Product Or Service= Capitalequipmentrevenues;
0001757898-25-000005 20230331 Revenues 536704000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Revenues 147420000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Product Or Service= Capitalequipmentrevenues;
0001757898-25-000005 20240331 Revenues 5138701000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Revenues 0.0000 USD 4 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001757898-25-000005 20240331 Revenues 3751437000.0000 USD 4 us-gaap/2024 Geographical= U S;
0001757898-25-000005 20250331 Revenues 5459515000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Revenues 138081000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Product Or Service= Servicerevenues;
0001757898-25-000005 20250331 Revenues 2871604000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001757898-25-000005 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4742920000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Accrued Income Taxes Current 13640000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Allowance For Doubtful Accounts Receivable Current 22984000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Assets 3340369000.0000 USD 0 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 171701000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Commitments And Contingencies USD 0 us-gaap/2024
0001757898-25-000005 20240331 Common Stock Dividends Per Share Cash Paid 2.0300 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Common Stock Dividends Per Share Declared 2.0300 USD 4 us-gaap/2024
0001757898-25-000005 20220331 Common Stock Shares Outstanding 100067000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20250331 Common Stock Shares Outstanding 98301000.0000 shares 0 us-gaap/2024
0001757898-25-000005 20250331 Earnings Per Share Basic 6.2400 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Earnings Per Share Diluted 3.8100 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Gain Loss On Disposition Of Business And Equity Investments Net 67000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20250331 Gain Loss On Sale Of Property Plant Equipment -5735000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Goodwill 197067000.0000 USD 0 us-gaap/2024 Business Acquisition= B D Acquisition;
0001757898-25-000005 20250331 Goodwill 1415442000.0000 USD 0 us-gaap/2024 Reporting Unit= Applied Sterilization Technologies;
0001757898-25-000005 20230331 Goodwill Impairment Loss 48922000.0000 USD 4 us-gaap/2024 Geographical= Otherforeignlocations;
0001757898-25-000005 20250331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 796207000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 4517000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 4517000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Heldforsale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Discontinued Operations Dental Segment;
0001757898-25-000005 20250331 Income Loss From Discontinued Operations Net Of Tax Per Diluted Share 0.0500 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Increase Decrease In Accounts Payable 33589000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Increase Decrease In Accrued Liabilities -22054000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Increase Decrease In Noncontrolling Interests Other 296000.0000 USD 4 0001757898-25-000005 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20250331 Liabilities 3531054000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Liabilities Current 931127000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Loss On Classification As Held For Sale 0.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20240331 Loss On Classification As Held For Sale 206444000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20230331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 794000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Net Cash Provided By Used In Financing Activities -1572364000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Net Income Loss 378239000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Noncontrolling Interest Increase From Contributions To Noncontrolling Interest Holders 2994000.0000 USD 4 0001757898-25-000005 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20240331 Nonoperating Income Expense -133308000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Operating Expenses 1382042000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Operating Income Loss 791101000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Operating Lease Liability Current 34202000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230930 Operating Lease Right Of Use Asset 0.0000 USD 0 us-gaap/2024 Business Acquisition= B D Acquisition;
0001757898-25-000005 20230331 Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax -109638000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest 7947000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001757898-25-000005 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -110902000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 736000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001757898-25-000005 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 7211000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Translation Adjustment;
0001757898-25-000005 20240331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax -155000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Other Noncash Income Expense -12316000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Payments For Repurchase Of Private Placement 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Payments Of Merger Related Costs Financing Activities 1471000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Payments To Acquire Businesses Net Of Cash Acquired 546256000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Payments To Acquire Businesses Net Of Cash Acquired 539758000.0000 USD 4 us-gaap/2024 Asset Acquisition= B D Acquisition;
0001757898-25-000005 20250331 Payments To Acquire Businesses Net Of Cash Acquired 54139000.0000 USD 4 us-gaap/2024 Business Acquisition= Other F Y25 Acquisition;
0001757898-25-000005 20240331 Payments To Minority Shareholders 1561000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Payments To Minority Shareholders 2069000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Proceeds From Divestiture Of Businesses 9458000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Proceeds From Minority Shareholders 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Proceeds From Payments For Other Financing Activities 10472000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Repayments Of Term Loans 638125000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20250331 Research And Development Expense 93092000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Revenues 26460000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Product Or Service= Capitalequipmentrevenues;
0001757898-25-000005 20230331 Revenues 1050316000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment; Product Or Service= Consumablerevenues;
0001757898-25-000005 20230331 Revenues 0.0000 USD 4 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001757898-25-000005 20230331 Revenues 1207601000.0000 USD 4 us-gaap/2024 Geographical= Otherforeignlocations;
0001757898-25-000005 20240331 Revenues 953980000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies;
0001757898-25-000005 20250331 Revenues 1007627000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Product Or Service= Servicerevenues;
0001757898-25-000005 20250331 Revenues 4007622000.0000 USD 4 us-gaap/2024 Geographical= U S;
0001757898-25-000005 20230331 Selling General And Administrative Expense 43804000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4486375000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Stock Issued During Period Shares Employee Stock Purchase Plans 331000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Stock Issued During Period Value Employee Stock Purchase Plan 67009000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20230331 Stock Repurchased And Retired During Period Value 308565000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Stock Repurchased And Retired During Period Value 297322000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Stock Repurchased And Retired During Period Value 1557000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20230331 Accumulated Other Comprehensive Income Loss Net Of Tax -320710000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 208357000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Common Stock Dividends Per Share Cash Paid 1.8400 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Common Stock Shares Outstanding 98883000.0000 shares 0 us-gaap/2024
0001757898-25-000005 20250331 Common Stock Value 4420413000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Comprehensive Income Net Of Tax -3872000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Cost Of Goods And Services Sold 2555540000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Cost Of Goods And Services Sold 2920541000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Cost Of Goods And Services Sold 1404459000.0000 USD 4 us-gaap/2024 Product Or Service= Service;
0001757898-25-000005 20250331 Cost Of Goods And Services Sold 1514275000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001757898-25-000005 20230331 Deferred Income Tax Expense Benefit -185913000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Depreciation Depletion And Amortization 422530000.0000 USD 4 us-gaap/2024 Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20240331 Depreciation Depletion And Amortization 450067000.0000 USD 4 us-gaap/2024 Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20250331 Depreciation Depletion And Amortization 476215000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Depreciation Depletion And Amortization 334212000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Productsand Life Sciences; Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20240331 Dividends Common Stock Cash 200570000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20230331 Gain Loss On Sale Of Property Plant Equipment -22193000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Goodwill 4863000.0000 USD 0 us-gaap/2024 Business Acquisition= Series Of Individually Immaterial Business Acquisitions;
0001757898-25-000005 20240331 Income Loss From Continuing Operations Per Diluted Share 5.5500 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity -450384000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Heldforsale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Discontinued Operations Dental Segment;
0001757898-25-000005 20240331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity -173201000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Increase Decrease In Accounts Receivable 28815000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Increase Decrease In Prepaid Deferred Expense And Other Assets 24086000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets 50272000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Interest Expense Nonoperating 144351000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Inventory Net 674535000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Liabilities And Stockholders Equity 10146811000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Litigation Settlement Loss 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 1562000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Net Income Loss 107030000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Net Income Loss Attributable To Noncontrolling Interest 1840000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Noncontrolling Interest Decrease From Divestiture Of Joint Venture Interest 2639000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20250331 Operating Lease Right Of Use Asset 156388000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent -7947000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Payments For Repurchase Of Common Stock 308565000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Payments For Repurchase Of Common Stock 211321000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Payments To Acquire Businesses Net Of Cash Acquired 42572000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Payments To Acquire Businesses Net Of Cash Acquired 6498000.0000 USD 4 us-gaap/2024 Business Acquisition= Series Of Individually Immaterial Business Acquisitions;
0001757898-25-000005 20240331 Payments To Acquire Investments 1500000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Payments To Acquire Property Plant And Equipment 360326000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Proceeds From Minority Shareholders 2532000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Proceeds From Payments For Other Financing Activities 25469000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Proceeds From Repayments Of Lines Of Credit 181486000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Proceeds From Sale Of Other Investments 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Profit Loss 105813000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Profit Loss 380079000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Profit Loss 1840000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20240331 Repayments Of Term Loans 60000000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20230331 Research And Development Expense 84675000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare; Consolidation Items= Operating Segments;
0001757898-25-000005 20240331 Research And Development Expense 89771000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Revenues 914431000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Revenues 887971000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Product Or Service= Servicerevenues;
0001757898-25-000005 20230331 Revenues 536704000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member;
0001757898-25-000005 20240331 Revenues 3613019000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment;
0001757898-25-000005 20240331 Revenues 571702000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member;
0001757898-25-000005 20250331 Revenues 3878671000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare; Consolidation Items= Operating Segments;
0001757898-25-000005 20250331 Revenues 1445440000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment; Product Or Service= Servicerevenues;
0001757898-25-000005 20250331 Revenues 286656000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Product Or Service= Consumablerevenues;
0001757898-25-000005 20250331 Revenues 0.0000 USD 4 us-gaap/2024 Consolidation Items= Corporate Non Segment;
0001757898-25-000005 20230331 Selling General And Administrative Expense 1090663000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Selling General And Administrative Expense 609974000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -320710000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001757898-25-000005 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -328657000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001757898-25-000005 20250331 Stock Issued During Period Value Employee Stock Purchase Plan 82870000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Stock Repurchased And Retired During Period Shares 1002000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20230331 Stock Repurchased And Retired During Period Value 11243000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20240331 Stock Repurchased And Retired During Period Value 10208000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20250331 Stock Repurchased And Retired During Period Value 212714000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Share Based Compensation 57397000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Accrued Liabilities Current 368068000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20220331 Accumulated Other Comprehensive Income Loss Net Of Tax -209808000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Allowance For Doubtful Accounts Receivable Current 24354000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Assets 6806442000.0000 USD 0 us-gaap/2024 Business Segments= Healthcare Productsand Life Sciences; Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 207020000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Commitments And Contingencies 110402000.0000 USD 0 us-gaap/2024 Purchase Commitment Excluding Longterm Commitment= Commercial Commitments;
0001757898-25-000005 20250331 Common Stock Shares Authorized 500000000.0000 shares 0 us-gaap/2024
0001757898-25-000005 20250331 Common Stock Shares Outstanding 98301000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Cost Of Goods And Services Sold 1516082000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001757898-25-000005 20250331 Deferred Income Taxes And Other Tax Liabilities Noncurrent 403654000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Depreciation Depletion And Amortization 552897000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Dividends Common Stock Cash 219875000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20230331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -14862000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Gain Loss On Sale Of Business And Equity Investments Continuing Operations 7425000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20230331 Goodwill 2301273000.0000 USD 0 us-gaap/2024 Reporting Unit= Health Care;
0001757898-25-000005 20230331 Goodwill Impairment Loss 490565000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Gross Profit 2218160000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest 611557000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Income Loss From Discontinued Operations Net Of Tax Per Diluted Share -4.4900 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Increase Decrease In Inventories 123921000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Increase Decrease In Noncontrolling Interests Other 64000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20250331 Increase Decrease In Noncontrolling Interests Other 87000.0000 USD 4 0001757898-25-000005 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20230331 Interest Expense Nonoperating 107956000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Liabilities 4748351000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Liabilities And Stockholders Equity 11063697000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Liabilities Current 1022173000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Net Cash Provided By Used In Financing Activities -498718000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Net Cash Provided By Used In Operating Activities 1148087000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Nonoperating Income Expense -70434000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Operating Expenses 1189625000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Operating Income Loss 866641000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Other Assets Noncurrent 66199000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax -736000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax 36170000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Other Liabilities Noncurrent 61889000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Payments For Repurchase Of Private Placement 91000000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Payments Of Dividends Common Stock 200570000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Payments Of Merger Related Costs Financing Activities 355000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Proceeds From Divestiture Of Businesses 41894000.0000 USD 4 us-gaap/2024 Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= C E C S;
0001757898-25-000005 20240331 Proceeds From Minority Shareholders 2994000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Proceeds From Payments For Other Financing Activities 1828000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Proceeds From Sale Of Other Investments 3882000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Proceeds From Sale Of Property Plant And Equipment 7381000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Profit Loss 1433000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20230331 Revenues 1138225000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment; Product Or Service= Servicerevenues;
0001757898-25-000005 20240331 Revenues 14519000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Product Or Service= Capitalequipmentrevenues;
0001757898-25-000005 20240331 Revenues 1248424000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment; Product Or Service= Consumablerevenues;
0001757898-25-000005 20240331 Revenues 155520000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Product Or Service= Capitalequipmentrevenues;
0001757898-25-000005 20250331 Revenues 30946000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Product Or Service= Capitalequipmentrevenues;
0001757898-25-000005 20250331 Revenues 2587911000.0000 USD 4 us-gaap/2024 Product Or Service= Service;
0001757898-25-000005 20250331 Short Term Borrowings 125000000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 6087172000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 2087645000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20230331 Stock Issued During Period Shares Employee Stock Purchase Plans 204000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Stock Issued During Period Value Employee Stock Purchase Plan 67009000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Stock Repurchased And Retired During Period Value 11765000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Income Tax Expense Benefit 184650000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Increase Decrease In Accounts Payable -18962000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Increase Decrease In Accounts Receivable 128069000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Increase Decrease In Accrued Liabilities 38939000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Increase Decrease In Inventories -73072000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Intangible Assets Net Excluding Goodwill 1854390000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Inventory Net 581329000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Liabilities Of Disposal Group Including Discontinued Operation Current 64012000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Liabilities Of Disposal Group Including Discontinued Operation Current 0.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Litigation Settlement Loss 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Net Income Loss Attributable To Noncontrolling Interest -1217000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Noncontrolling Interest Decrease From Divestiture Of Joint Venture Interest 2639000.0000 USD 4 0001757898-25-000005 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20250331 Noncontrolling Interest Increase From Contributions To Noncontrolling Interest Holders 2532000.0000 USD 4 0001757898-25-000005 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest 110902000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001757898-25-000005 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest -36319000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax -144000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Other Noncash Income Expense 24832000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Payments To Acquire Businesses Net Of Cash Acquired 54139000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Payments To Acquire Investments 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Proceeds From Divestiture Of Businesses 6624000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Proceeds From Sale Of Property Plant And Equipment 14587000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Profit Loss -1217000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20250331 Profit Loss 614641000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20240331 Property Plant And Equipment Net 68603000.0000 USD 0 us-gaap/2024 Geographical= I E;
0001757898-25-000005 20230331 Research And Development Expense 4925000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Research And Development Expense 7413000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Consolidation Items= Operating Segments;
0001757898-25-000005 20230331 Revenues 241114000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Product Or Service= Consumablerevenues;
0001757898-25-000005 20240331 Revenues 953980000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Consolidation Items= Operating Segments;
0001757898-25-000005 20240331 Revenues 1304569000.0000 USD 4 us-gaap/2024 Geographical= Otherforeignlocations;
0001757898-25-000005 20250331 Revenues 1037200000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment; Product Or Service= Capitalequipmentrevenues;
0001757898-25-000005 20250331 Revenues 117534000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Product Or Service= Capitalequipmentrevenues;
0001757898-25-000005 20250331 Revenues 107321000.0000 USD 4 us-gaap/2024 Geographical= I E;
0001757898-25-000005 20230331 Selling General And Administrative Expense 52608000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Consolidation Items= Operating Segments;
0001757898-25-000005 20240331 Selling General And Administrative Expense 568040000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare; Consolidation Items= Operating Segments;
0001757898-25-000005 20240331 Share Based Compensation 56535000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 12281000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 4543176000.0000 USD 0 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 13182000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20250331 Stock Repurchased And Retired During Period Value 205633000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Accounts Receivable Net Current 1008315000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Amortization Of Inventory Fair Value Adjustments 0.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20240331 Assets 11063697000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Assets 7055576000.0000 USD 0 us-gaap/2024 Business Segments= Healthcare Productsand Life Sciences; Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20250331 Assets 10146811000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Assets Of Disposal Group Including Discontinued Operation Current 804904000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Assets Of Disposal Group Including Discontinued Operation Current 0.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -139963000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Commitments And Contingencies USD 0 us-gaap/2024
0001757898-25-000005 20250331 Common Stock Dividends Per Share Cash Paid 2.2300 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Common Stock Dividends Per Share Declared 2.2300 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Common Stock Shares Outstanding 98883000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20250331 Comprehensive Income Net Of Tax 650960000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Cost Of Goods And Services Sold 1271363000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001757898-25-000005 20250331 Cost Of Goods And Services Sold 3056751000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Deferred Income Taxes And Other Tax Liabilities Noncurrent 479688000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Deferred Income Tax Expense Benefit -76546000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Depreciation Depletion And Amortization 116153000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20250331 Depreciation Depletion And Amortization 476215000.0000 USD 4 us-gaap/2024 Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20230331 Dividends Common Stock Cash 183498000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Earnings Per Share Diluted 1.0700 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Gain Loss On Sale Of Business And Equity Investments Continuing Operations 0.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20230331 Goodwill 1396134000.0000 USD 0 us-gaap/2024 Reporting Unit= Applied Sterilization Technologies;
0001757898-25-000005 20230930 Goodwill 202399000.0000 USD 0 us-gaap/2024 Business Acquisition= B D Acquisition;
0001757898-25-000005 20240331 Goodwill 1387629000.0000 USD 0 us-gaap/2024 Reporting Unit= Applied Sterilization Technologies;
0001757898-25-000005 20240331 Goodwill 182173000.0000 USD 0 us-gaap/2024 Reporting Unit= Life Sciences;
0001757898-25-000005 20250331 Goodwill 4095678000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Gross Profit 2402764000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 680266000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest 702810000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Income Loss From Continuing Operations Per Basic Share 6.1900 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Income Loss From Continuing Operations Per Diluted Share 5.5600 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Income Loss From Discontinued Operations Net Of Tax Per Basic Share 0.0500 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Accounts Payable Current 280770000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20220331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 348320000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -35319000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Common Stock Dividends Per Share Declared 1.8400 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Common Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Common Stock Shares Issued 98883000.0000 shares 0 us-gaap/2024
0001757898-25-000005 20240331 Deferred Income Tax Expense Benefit -131412000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Depreciation Depletion And Amortization 322244000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Productsand Life Sciences; Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20240331 Dividends Common Stock Cash 200570000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Dividends Common Stock Cash 219875000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents -2064000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Gain Loss On Disposition Of Business And Equity Investments Net -327000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20240331 Gain Loss On Sale Of Property Plant Equipment -24997000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Goodwill 10610000.0000 USD 0 us-gaap/2024 Business Acquisition= Series Of Individually Immaterial Business Acquisitions;
0001757898-25-000005 20240331 Goodwill Impairment Loss 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest 556197000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest 553280000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Income Loss From Continuing Operations Per Basic Share 5.5800 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Income Loss From Continuing Operations Per Diluted Share 6.1600 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity -173201000.0000 USD 4 us-gaap/2024 Disposal Group Classification= Discontinued Operations Heldforsale; Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Discontinued Operations Dental Segment;
0001757898-25-000005 20240331 Income Loss From Discontinued Operations Net Of Tax Per Diluted Share -1.7400 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Income Tax Expense Benefit 124069000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Increase Decrease In Accrued Liabilities 39955000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Increase Decrease In Inventories 37450000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Increase Decrease In Noncontrolling Interests Other 87000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20250331 Minority Interest 12352000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 1562000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20250331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 2069000.0000 USD 4 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20250331 Noncontrolling Interest Increase From Contributions To Noncontrolling Interest Holders 2532000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20240331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest 7947000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 36319000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Other Noncash Income Expense 3745000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Other Nonoperating Income Expense 11043000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Other Nonoperating Income Expense 8402000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Other Prepaid Expense Current 203774000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Payments For Repurchase Of Private Placement 80000000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Payments Of Financing Costs 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Payments To Acquire Property Plant And Equipment 370091000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Payments To Minority Shareholders 794000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Proceeds From Repayments Of Lines Of Credit -446304000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Proceeds From Sale Of Property Plant And Equipment 9195000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Profit Loss 616074000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Property Plant And Equipment Net 1956544000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Property Plant And Equipment Net 74901000.0000 USD 0 us-gaap/2024 Geographical= I E;
0001757898-25-000005 20240331 Research And Development Expense 4141000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Consolidation Items= Operating Segments;
0001757898-25-000005 20250331 Research And Development Expense 107648000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Retained Earnings Accumulated Deficit 2087645000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Revenues 4536266000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Revenues 12000000.0000 USD 4 us-gaap/2024 Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= Animal Health Divestiture;
0001757898-25-000005 20240331 Revenues 1091537000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment; Product Or Service= Capitalequipmentrevenues;
0001757898-25-000005 20240331 Revenues 571702000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Consolidation Items= Operating Segments;
0001757898-25-000005 20240331 Revenues 251580000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Product Or Service= Consumablerevenues;
0001757898-25-000005 20240331 Revenues 82695000.0000 USD 4 us-gaap/2024 Geographical= I E;
0001757898-25-000005 20240331 Revenues 35000000.0000 USD 4 us-gaap/2024 Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations= C E C S;
0001757898-25-000005 20250331 Revenues 1038573000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Consolidation Items= Operating Segments;
0001757898-25-000005 20250331 Revenues 1396031000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment; Product Or Service= Consumablerevenues;
0001757898-25-000005 20250331 Revenues 542271000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Consolidation Items= Operating Segments;
0001757898-25-000005 20240331 Selling General And Administrative Expense 1252318000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -209808000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001757898-25-000005 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 2475330000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20230331 Stock Issued During Period Value Employee Stock Purchase Plan 40777000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Stock Issued During Period Value Employee Stock Purchase Plan 82870000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Stock Repurchased And Retired During Period Shares 77000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20250331 Stock Repurchased And Retired During Period Value 7081000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20250331 Accounts Receivable Net Current 1043961000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Accumulated Other Comprehensive Income Loss Net Of Tax -328657000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Assets Current 2000765000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Common Stock Shares Outstanding 98629000.0000 shares 0 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20240331 Comprehensive Income Net Of Tax 370292000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Depreciation Depletion And Amortization 306377000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Productsand Life Sciences; Operating Activities Segment= Segment Continuing Operations;
0001757898-25-000005 20240331 Depreciation Depletion And Amortization 565244000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 185000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Employee Related Liabilities Current 192677000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Goodwill 2503000.0000 USD 0 us-gaap/2024 Business Acquisition= Series Of Individually Immaterial Business Acquisitions;
0001757898-25-000005 20250331 Goodwill 2509308000.0000 USD 0 us-gaap/2024 Reporting Unit= Health Care;
0001757898-25-000005 20250331 Goodwill Impairment Loss 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Gross Profit 1980726000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Income Loss From Discontinued Operations Net Of Tax Per Basic Share -1.7500 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Income Tax Expense Benefit 149530000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Increase Decrease In Accounts Receivable 133304000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Increase Decrease In Noncontrolling Interests Other 296000.0000 USD 4 0001757898-25-000005
0001757898-25-000005 20250331 Litigation Settlement Loss 48150000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Minority Interest 13182000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Minority Interest Decrease From Distributions To Noncontrolling Interest Holders 2069000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Net Cash Provided By Used In Investing Activities -887361000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Net Cash Provided By Used In Operating Activities 973274000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Nonoperating Income Expense -110835000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Operating Income Loss 836118000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Operating Lease Liability Current 31239000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Operating Lease Liability Noncurrent 124637000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20250331 Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax 149000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest 110902000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent 1264000.0000 USD 4 us-gaap/2024 Equity Components= Accumulated Defined Benefit Plans Adjustment;
0001757898-25-000005 20230331 Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax 521000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Other Nonoperating Income Expense -2879000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Payments Of Dividends Common Stock 183498000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Payments Of Financing Costs 2316000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Proceeds From Repayments Of Lines Of Credit 241657000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20230331 Proceeds From Sale Of Other Investments 0.0000 USD 4 us-gaap/2024
0001757898-25-000005 20240331 Profit Loss 378239000.0000 USD 4 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20250331 Property Plant And Equipment Net 1008712000.0000 USD 0 us-gaap/2024 Geographical= U S;
0001757898-25-000005 20240331 Research And Development Expense 103679000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Research And Development Expense 3808000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Consolidation Items= Operating Segments;
0001757898-25-000005 20250331 Research And Development Expense 9361000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Consolidation Items= Operating Segments;
0001757898-25-000005 20250331 Restructuring Costs 46049000.0000 USD 4 us-gaap/2024
0001757898-25-000005 20250331 Retained Earnings Accumulated Deficit 2475330000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20230331 Revenues 914431000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies;
0001757898-25-000005 20230331 Revenues 3085131000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment;
0001757898-25-000005 20240331 Revenues 939461000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Product Or Service= Servicerevenues;
0001757898-25-000005 20240331 Revenues 3613019000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare; Consolidation Items= Operating Segments;
0001757898-25-000005 20240331 Revenues 2763954000.0000 USD 4 us-gaap/2024 Product Or Service= Product;
0001757898-25-000005 20250331 Revenues 3878671000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare Segment;
0001757898-25-000005 20230331 Selling General And Administrative Expense 506262000.0000 USD 4 us-gaap/2024 Business Segments= Healthcare; Consolidation Items= Operating Segments;
0001757898-25-000005 20240331 Selling General And Administrative Expense 51698000.0000 USD 4 us-gaap/2024 Business Segments= Applied Sterilization Technologies; Consolidation Items= Operating Segments;
0001757898-25-000005 20250331 Selling General And Administrative Expense 59755000.0000 USD 4 us-gaap/2024 Business Segments= Life Science Member; Consolidation Items= Operating Segments;
0001757898-25-000005 20240331 Short Term Borrowings 85938000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20240331 Stockholders Equity 6302164000.0000 USD 0 us-gaap/2024
0001757898-25-000005 20220331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 1999244000.0000 USD 0 us-gaap/2024 Equity Components= Retained Earnings;
0001757898-25-000005 20230331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 9974000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest -292338000.0000 USD 0 us-gaap/2024 Equity Components= Accumulated Other Comprehensive Income;
0001757898-25-000005 20250331 Stockholders Equity Including Portion Attributable To Noncontrolling Interest 12352000.0000 USD 0 us-gaap/2024 Equity Components= Noncontrolling Interest;
0001757898-25-000005 20230331 Stock Issued During Period Value Employee Stock Purchase Plan 40777000.0000 USD 4 us-gaap/2024 Equity Components= Common Stock;
0001757898-25-000005 20230331 Stock Repurchased And Retired During Period Shares 1642000.0000 shares 4 us-gaap/2024 Equity Components= Common Stock;

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Increase Decrease In Accounts Receivable us-gaap/2024 0 0 monetary D C Increase (Decrease) in Accounts Receivable The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
Assets Current us-gaap/2024 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary I D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Operating Lease Liability Current us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Current Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.
Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.
Payments To Acquire Businesses Net Of Cash Acquired us-gaap/2024 0 0 monetary D C Payments to Acquire Businesses, Net of Cash Acquired The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.
Payments To Acquire Property Plant And Equipment us-gaap/2024 0 0 monetary D C Payments to Acquire Property, Plant, and Equipment The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Proceeds From Minority Shareholders us-gaap/2024 0 0 monetary D D Proceeds from Noncontrolling Interests Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.
Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary I C Equity, Including Portion Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Allowance For Doubtful Accounts Receivable Current us-gaap/2024 0 0 monetary I C Accounts Receivable, Allowance for Credit Loss, Current Amount of allowance for credit loss on accounts receivable, classified as current.
Comprehensive Income Net Of Tax us-gaap/2024 0 0 monetary D C Comprehensive Income (Loss), Net of Tax, Attributable to Parent Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Liabilities us-gaap/2024 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Liabilities And Stockholders Equity us-gaap/2024 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Liabilities Of Disposal Group Including Discontinued Operation Current us-gaap/2024 0 0 monetary I C Disposal Group, Including Discontinued Operation, Liabilities, Current Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D D Net Income (Loss) Attributable to Noncontrolling Interest Amount of Net Income (Loss) attributable to noncontrolling interest.
Retained Earnings Accumulated Deficit us-gaap/2024 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Gain Loss On Sale Of Business And Equity Investments Continuing Operations 0001757898-25-000005 1 0 monetary D C Gain (Loss) On Sale Of Business and Equity Investments, Continuing Operations Gain (Loss) On Sale Of Business and Equity Investments, Continuing Operations
Gain Loss On Disposition Of Business And Equity Investments Net 0001757898-25-000005 1 0 monetary D C Gain (Loss) on Disposition of Business And Equity Investments, Net Gain (Loss) on Disposition of Business And Equity Investments, Net
Accounts Receivable Net Current us-gaap/2024 0 0 monetary I D Accounts Receivable, after Allowance for Credit Loss, Current Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Common Stock Dividends Per Share Declared us-gaap/2024 0 0 perShare D Common Stock, Dividends, Per Share, Declared Aggregate dividends declared during the period for each share of common stock outstanding.
Common Stock Par Or Stated Value Per Share us-gaap/2024 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Common Stock Shares Outstanding us-gaap/2024 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Income Tax Expense (Benefit) Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Net Income Loss us-gaap/2024 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Payments To Acquire Investments us-gaap/2024 0 0 monetary D C Payments to Acquire Investments The cash outflow associated with the purchase of all investments (debt, security, other) during the period.
Proceeds From Sale Of Other Investments us-gaap/2024 0 0 monetary D D Proceeds from Sale of Other Investments Amount of cash inflow from the sale of investments classified as other.
Stockholders Equity us-gaap/2024 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Stock Issued During Period Value Employee Stock Purchase Plan us-gaap/2024 0 0 monetary D C Stock Issued During Period, Value, Employee Stock Purchase Plan Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.
Repayments Of Term Loans 0001757898-25-000005 1 0 monetary D C Repayments of Term Loans Repayments of Term Loans
Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 0 0 monetary I C Accumulated Other Comprehensive Income (Loss), Net of Tax Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
Assets us-gaap/2024 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Common Stock Dividends Per Share Cash Paid us-gaap/2024 0 0 perShare D Common Stock, Dividends, Per Share, Cash Paid Aggregate dividends paid during the period for each share of common stock outstanding.
Common Stock Shares Issued us-gaap/2024 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Cost Of Goods And Services Sold us-gaap/2024 0 0 monetary D D Cost of Goods and Services Sold The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
Dividends Common Stock Cash us-gaap/2024 0 0 monetary D D Dividends, Common Stock, Cash Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.
Earnings Per Share Diluted us-gaap/2024 0 0 perShare D Earnings Per Share, Diluted The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 0 0 monetary D D Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Gross Profit us-gaap/2024 0 0 monetary D C Gross Profit Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
Operating Lease Right Of Use Asset us-gaap/2024 0 0 monetary I D Operating Lease, Right-of-Use Asset Amount of lessee's right to use underlying asset under operating lease.
Other Assets Noncurrent us-gaap/2024 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Stock Repurchased And Retired During Period Shares us-gaap/2024 0 0 shares D Stock Repurchased and Retired During Period, Shares Number of shares that have been repurchased and retired during the period.
Accrued Liabilities Current us-gaap/2024 0 0 monetary I C Accrued Liabilities, Current Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Depreciation Depletion And Amortization us-gaap/2024 0 0 monetary D D Depreciation, Depletion and Amortization The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
Goodwill Impairment Loss us-gaap/2024 0 0 monetary D D Goodwill, Impairment Loss Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Income Loss From Continuing Operations Per Diluted Share us-gaap/2024 0 0 perShare D Income (Loss) from Continuing Operations, Per Diluted Share The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share us-gaap/2024 0 0 perShare D Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
Interest Expense Nonoperating us-gaap/2024 0 0 monetary D D Interest Expense, Nonoperating Amount of interest expense classified as nonoperating.
Liabilities Current us-gaap/2024 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Payments To Minority Shareholders us-gaap/2024 0 0 monetary D C Payments to Noncontrolling Interests Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.
Proceeds From Repayments Of Lines Of Credit us-gaap/2024 0 0 monetary D D Proceeds from (Repayments of) Lines of Credit The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).
Selling General And Administrative Expense us-gaap/2024 0 0 monetary D D Selling, General and Administrative Expense The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
Share Based Compensation us-gaap/2024 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Increase Decrease In Inventories us-gaap/2024 0 0 monetary D C Increase (Decrease) in Inventories The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Minority Interest Decrease From Distributions To Noncontrolling Interest Holders us-gaap/2024 0 0 monetary D D Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.
Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Nonoperating Income (Expense) The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Other Noncash Income Expense us-gaap/2024 0 0 monetary D C Other Noncash Income (Expense) Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.
Proceeds From Sale Of Property Plant And Equipment us-gaap/2024 0 0 monetary D D Proceeds from Sale of Property, Plant, and Equipment The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
Profit Loss us-gaap/2024 0 0 monetary D C Net Income (Loss), Including Portion Attributable to Noncontrolling Interest The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
Stock Repurchased And Retired During Period Value us-gaap/2024 0 0 monetary D D Stock Repurchased and Retired During Period, Value Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).
Accrued Income Taxes Current us-gaap/2024 0 0 monetary I C Accrued Income Taxes, Current Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.
Assets Of Disposal Group Including Discontinued Operation Current us-gaap/2024 0 0 monetary I D Disposal Group, Including Discontinued Operation, Assets, Current Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.
Deferred Income Tax Expense Benefit us-gaap/2024 0 0 monetary D D Deferred Income Tax Expense (Benefit) Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Employee Related Liabilities Current us-gaap/2024 0 0 monetary I C Employee-related Liabilities, Current Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Goodwill us-gaap/2024 0 0 monetary I D Goodwill Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.
Intangible Assets Net Excluding Goodwill us-gaap/2024 0 0 monetary I D Intangible Assets, Net (Excluding Goodwill) Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
Litigation Settlement Loss us-gaap/2024 0 0 monetary D D Litigation Settlement, Loss Amount of loss from litigation settlement for amount awarded to other party. Excludes claims within an insurance entity's normal claims settlement process.
Net Cash Provided By Used In Operating Activities us-gaap/2024 0 0 monetary D Net Cash Provided by (Used in) Operating Activities Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Operating Expenses us-gaap/2024 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Operating Income Loss us-gaap/2024 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D D Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.
Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax us-gaap/2024 0 0 monetary D C Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.
Other Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Other Liabilities, Noncurrent Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
Noncontrolling Interest Decrease From Divestiture Of Joint Venture Interest 0001757898-25-000005 1 0 monetary D D Noncontrolling Interest, Decrease From Divestiture Of Joint Venture Interest Noncontrolling Interest, Decrease From Divestiture Of Joint Venture Interest
Proceeds From Payments For Other Financing Activities us-gaap/2024 0 0 monetary D D Proceeds from (Payments for) Other Financing Activities Amount of cash inflow (outflow) from financing activities classified as other.
Restructuring Costs us-gaap/2024 0 0 monetary D D Restructuring Costs Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
Short Term Borrowings us-gaap/2024 0 0 monetary I C Short-Term Debt Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
Accounts Payable Current us-gaap/2024 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Common Stock Value us-gaap/2024 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Income Loss From Continuing Operations Per Basic Share us-gaap/2024 0 0 perShare D Income (Loss) from Continuing Operations, Per Basic Share The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.
Inventory Net us-gaap/2024 0 0 monetary I D Inventory, Net Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Amount after tax of other comprehensive income (loss) attributable to parent entity.
Payments Of Merger Related Costs Financing Activities us-gaap/2024 0 0 monetary D C Payments of Merger Related Costs, Financing Activities The cash outflow for financing costs associated with business combinations.
Proceeds From Divestiture Of Businesses us-gaap/2024 0 0 monetary D D Proceeds from Divestiture of Businesses The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.
Research And Development Expense us-gaap/2024 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Revenues us-gaap/2024 0 0 monetary D C Revenues Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Amortization Of Inventory Fair Value Adjustments 0001757898-25-000005 1 0 monetary D D Amortization of inventory fair value adjustments Amortization of inventory fair value adjustments
Increase Decrease In Noncontrolling Interests Other 0001757898-25-000005 1 0 monetary D D Increase (Decrease) In Noncontrolling Interests, Other Increase (Decrease) In Noncontrolling Interests, Other
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 0 0 monetary D D Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Commitments And Contingencies us-gaap/2024 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Common Stock Shares Authorized us-gaap/2024 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Gain Loss On Sale Of Property Plant Equipment us-gaap/2024 0 0 monetary D C Gain (Loss) on Disposition of Property Plant Equipment Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest us-gaap/2024 0 0 monetary D C Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.
Income Loss From Discontinued Operations Net Of Tax Per Basic Share us-gaap/2024 0 0 perShare D Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.
Increase Decrease In Accounts Payable us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accounts Payable The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
Net Cash Provided By Used In Financing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Financing Activities Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax us-gaap/2024 0 0 monetary D C Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
Payments For Repurchase Of Common Stock us-gaap/2024 0 0 monetary D C Payments for Repurchase of Common Stock The cash outflow to reacquire common stock during the period.
Payments For Repurchase Of Private Placement us-gaap/2024 0 0 monetary D C Payments for Repurchase of Private Placement The cash outflow associated with the repurchase of amount received from entity's raising of capital via private rather than public placement.
Other Nonoperating Income Expense us-gaap/2024 0 0 monetary D C Other Nonoperating Income (Expense) Amount of income (expense) related to nonoperating activities, classified as other.
Other Prepaid Expense Current us-gaap/2024 0 0 monetary I D Other Prepaid Expense, Current Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
Earnings Per Share Basic us-gaap/2024 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Payments Of Financing Costs us-gaap/2024 0 0 monetary D C Payments of Financing Costs The cash outflow for loan and debt issuance costs.
Stock Issued During Period Shares Employee Stock Purchase Plans us-gaap/2024 0 0 shares D Stock Issued During Period, Shares, Employee Stock Purchase Plans Number of shares issued during the period as a result of an employee stock purchase plan.
Loss On Classification As Held For Sale 0001757898-25-000005 1 0 monetary D D Loss on classification as held for sale Loss on classification as held for sale
Net Cash Provided By Used In Investing Activities us-gaap/2024 0 0 monetary D D Net Cash Provided by (Used in) Investing Activities Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Noncontrolling Interest Increase From Contributions To Noncontrolling Interest Holders 0001757898-25-000005 1 0 monetary D C Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders
Deferred Income Taxes And Other Tax Liabilities Noncurrent us-gaap/2024 0 0 monetary I C Deferred Income Taxes and Other Tax Liabilities, Noncurrent Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity us-gaap/2024 0 0 monetary D C Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
Increase Decrease In Accrued Liabilities us-gaap/2024 0 0 monetary D D Increase (Decrease) in Accrued Liabilities The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
Long Term Debt Noncurrent us-gaap/2024 0 0 monetary I C Long-Term Debt, Excluding Current Maturities Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.
Minority Interest us-gaap/2024 0 0 monetary I C Equity, Attributable to Noncontrolling Interest Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
Operating Lease Liability Noncurrent us-gaap/2024 0 0 monetary I C Operating Lease, Liability, Noncurrent Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
Payments Of Dividends Common Stock us-gaap/2024 0 0 monetary D C Payments of Ordinary Dividends, Common Stock Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.
Property Plant And Equipment Net us-gaap/2024 0 0 monetary I D Property, Plant and Equipment, Net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001757898-25-000005 8 35 CF 0 H Payments Of Dividends Common Stock us-gaap/2024 Cash dividends paid to common shareholders 1
0001757898-25-000005 3 3 BS 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash and cash equivalents 0
0001757898-25-000005 3 4 BS 0 H Accounts Receivable Net Current us-gaap/2024 Accounts receivable (net of allowances of $24,354 and $22,984, respectively) 0
0001757898-25-000005 3 5 BS 0 H Inventory Net us-gaap/2024 Inventories, net 0
0001757898-25-000005 3 6 BS 0 H Other Prepaid Expense Current us-gaap/2024 Prepaid expenses and other current assets 0
0001757898-25-000005 3 7 BS 0 H Assets Of Disposal Group Including Discontinued Operation Current us-gaap/2024 Current assets held for sale 0
0001757898-25-000005 3 8 BS 0 H Assets Current us-gaap/2024 Total current assets 0
0001757898-25-000005 3 9 BS 0 H Property Plant And Equipment Net us-gaap/2024 Property, plant, and equipment, net 0
0001757898-25-000005 3 10 BS 0 H Operating Lease Right Of Use Asset us-gaap/2024 Operating Lease, Right-of-Use Asset 0
0001757898-25-000005 3 11 BS 0 H Goodwill us-gaap/2024 Goodwill 0
0001757898-25-000005 3 12 BS 0 H Intangible Assets Net Excluding Goodwill us-gaap/2024 Intangible Assets, Net (Excluding Goodwill) 0
0001757898-25-000005 3 13 BS 0 H Other Assets Noncurrent us-gaap/2024 Other assets 0
0001757898-25-000005 3 14 BS 0 H Assets us-gaap/2024 Assets 0
0001757898-25-000005 3 17 BS 0 H Accounts Payable Current us-gaap/2024 Accounts payable 0
0001757898-25-000005 3 18 BS 0 H Accrued Income Taxes Current us-gaap/2024 Accrued Income Taxes, Current 0
0001757898-25-000005 3 19 BS 0 H Employee Related Liabilities Current us-gaap/2024 Accrued payroll and other related liabilities 0
0001757898-25-000005 3 20 BS 0 H Operating Lease Liability Current us-gaap/2024 Capital Lease Obligations, Current 0
0001757898-25-000005 3 21 BS 0 H Short Term Borrowings us-gaap/2024 Short-term Debt 0
0001757898-25-000005 3 22 BS 0 H Accrued Liabilities Current us-gaap/2024 Accrued expenses and other 0
0001757898-25-000005 3 23 BS 0 H Liabilities Of Disposal Group Including Discontinued Operation Current us-gaap/2024 Current liabilities held for sale 0
0001757898-25-000005 3 24 BS 0 H Liabilities Current us-gaap/2024 Total current liabilities 0
0001757898-25-000005 3 25 BS 0 H Long Term Debt Noncurrent us-gaap/2024 Long-term indebtedness 0
0001757898-25-000005 3 26 BS 0 H Deferred Income Taxes And Other Tax Liabilities Noncurrent us-gaap/2024 Deferred income taxes, net 0
0001757898-25-000005 3 27 BS 0 H Operating Lease Liability Noncurrent us-gaap/2024 Capital Lease Obligations, Noncurrent 0
0001757898-25-000005 3 28 BS 0 H Other Liabilities Noncurrent us-gaap/2024 Other Liabilities, Noncurrent 0
0001757898-25-000005 3 29 BS 0 H Liabilities us-gaap/2024 Total liabilities 0
0001757898-25-000005 3 30 BS 0 H Commitments And Contingencies us-gaap/2024 Commitments and contingencies (see note 10) 0
0001757898-25-000005 3 31 BS 0 H Common Stock Value us-gaap/2024 Ordinary shares, with $0.001 par value; 500,000 shares authorized; 98,301 and 98,883 ordinary shares issued and outstanding, respectively 0
0001757898-25-000005 3 32 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2024 Retained earnings 0
0001757898-25-000005 3 33 BS 0 H Accumulated Other Comprehensive Income Loss Net Of Tax us-gaap/2024 Accumulated other comprehensive income 0
0001757898-25-000005 3 34 BS 0 H Stockholders Equity us-gaap/2024 Total shareholders' equity 0
0001757898-25-000005 3 35 BS 0 H Minority Interest us-gaap/2024 Noncontrolling interest 0
0001757898-25-000005 3 36 BS 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 0
0001757898-25-000005 3 37 BS 0 H Liabilities And Stockholders Equity us-gaap/2024 Total liabilities and equity 0
0001757898-25-000005 4 1 BS 1 H Allowance For Doubtful Accounts Receivable Current us-gaap/2024 Accounts Receivable, Allowance for Credit Loss, Current 0
0001757898-25-000005 4 2 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2024 Common Stock, Par or Stated Value Per Share 0
0001757898-25-000005 4 3 BS 1 H Common Stock Shares Authorized us-gaap/2024 Common Stock, Shares Authorized 0
0001757898-25-000005 4 4 BS 1 H Common Stock Shares Issued us-gaap/2024 Common shares issued 0
0001757898-25-000005 4 5 BS 1 H Common Stock Shares Outstanding us-gaap/2024 Common shares outstanding 0
0001757898-25-000005 5 8 IS 0 H Revenues us-gaap/2024 Total revenues 0
0001757898-25-000005 5 10 IS 0 H Cost Of Goods And Services Sold us-gaap/2024 Cost of revenues 0
0001757898-25-000005 5 11 IS 0 H Gross Profit us-gaap/2024 Gross Profit 0
0001757898-25-000005 5 13 IS 0 H Selling General And Administrative Expense us-gaap/2024 Selling, general, and administrative 0
0001757898-25-000005 5 14 IS 0 H Research And Development Expense us-gaap/2024 Research and development 0
0001757898-25-000005 5 15 IS 0 H Litigation Settlement Loss us-gaap/2024 Litigation Settlement, Loss 0
0001757898-25-000005 5 16 IS 0 H Restructuring Costs us-gaap/2024 Restructuring Costs 0
0001757898-25-000005 5 17 IS 0 H Operating Expenses us-gaap/2024 Total operating expenses 0
0001757898-25-000005 5 18 IS 0 H Operating Income Loss us-gaap/2024 Income (loss) from operations 0
0001757898-25-000005 5 20 IS 0 H Interest Expense Nonoperating us-gaap/2024 Interest expense 0
0001757898-25-000005 5 21 IS 0 H Other Nonoperating Income Expense us-gaap/2024 Interest income and miscellaneous expense 1
0001757898-25-000005 5 22 IS 0 H Gain Loss On Sale Of Business And Equity Investments Continuing Operations 0001757898-25-000005 Gain on sale of businesses and equity investment, net 0
0001757898-25-000005 5 23 IS 0 H Nonoperating Income Expense us-gaap/2024 Total non-operating expenses, net 1
0001757898-25-000005 5 24 IS 0 H Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest us-gaap/2024 Income (loss) before income tax expense (benefit) 0
0001757898-25-000005 5 25 IS 0 H Income Tax Expense Benefit us-gaap/2024 Income tax expense (benefit) 0
0001757898-25-000005 5 26 IS 0 H Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Income from continuing operations, net of income tax 0
0001757898-25-000005 5 27 IS 0 H Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity us-gaap/2024 Income (loss) from discontinued operations, net of income tax 0
0001757898-25-000005 5 28 IS 0 H Profit Loss us-gaap/2024 Net income 0
0001757898-25-000005 5 29 IS 0 H Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 Less: Net income (loss) attributable to noncontrolling interests 0
0001757898-25-000005 5 30 IS 0 H Net Income Loss us-gaap/2024 Net income attributable to shareholders 0
0001757898-25-000005 5 32 IS 0 H Income Loss From Continuing Operations Per Basic Share us-gaap/2024 Income (Loss) from Continuing Operations, Per Basic Share 0
0001757898-25-000005 5 33 IS 0 H Income Loss From Discontinued Operations Net Of Tax Per Basic Share us-gaap/2024 Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 0
0001757898-25-000005 5 34 IS 0 H Earnings Per Share Basic us-gaap/2024 Earnings Per Share, Basic 0
0001757898-25-000005 5 35 IS 0 H Income Loss From Continuing Operations Per Diluted Share us-gaap/2024 Income (Loss) from Continuing Operations, Per Diluted Share 0
0001757898-25-000005 5 36 IS 0 H Income Loss From Discontinued Operations Net Of Tax Per Diluted Share us-gaap/2024 Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share 0
0001757898-25-000005 5 37 IS 0 H Earnings Per Share Diluted us-gaap/2024 Earnings Per Share, Diluted 0
0001757898-25-000005 5 38 IS 0 H Common Stock Dividends Per Share Declared us-gaap/2024 Cash dividends declared per common share outstanding 0
0001757898-25-000005 6 1 CI 0 H Profit Loss us-gaap/2024 Income from continuing operations, net of income tax 0
0001757898-25-000005 6 2 CI 0 H Net Income Loss Attributable To Noncontrolling Interest us-gaap/2024 Less: Net income (loss) attributable to noncontrolling interests 0
0001757898-25-000005 6 3 CI 0 H Net Income Loss us-gaap/2024 Net income attributable to shareholders 0
0001757898-25-000005 6 4 CI 0 H Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax us-gaap/2024 Pension and postretirement benefit plan changes (net of taxes of $X, $(155), and $521, respectively) 0
0001757898-25-000005 6 5 CI 0 H Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax us-gaap/2024 Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax 0
0001757898-25-000005 6 6 CI 0 H Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent us-gaap/2024 Total other comprehensive income (loss) attributable to shareholders 0
0001757898-25-000005 6 7 CI 0 H Comprehensive Income Net Of Tax us-gaap/2024 Comprehensive Income (Loss), Net of Tax, Attributable to Parent 0
0001757898-25-000005 7 1 CI 1 H Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Tax us-gaap/2024 Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Tax 0
0001757898-25-000005 8 1 CF 0 H Profit Loss us-gaap/2024 Income from continuing operations, net of income tax 0
0001757898-25-000005 8 3 CF 0 H Depreciation Depletion And Amortization us-gaap/2024 Depreciation, depletion, and amortization 0
0001757898-25-000005 8 4 CF 0 H Deferred Income Tax Expense Benefit us-gaap/2024 Deferred income taxes 0
0001757898-25-000005 8 5 CF 0 H Share Based Compensation us-gaap/2024 Share-based compensation 0
0001757898-25-000005 8 6 CF 0 H Gain Loss On Sale Of Property Plant Equipment us-gaap/2024 Loss on the disposal of property, plant, equipment, and intangibles, net 1
0001757898-25-000005 8 7 CF 0 H Loss On Classification As Held For Sale 0001757898-25-000005 Loss on classification as held for sale 0
0001757898-25-000005 8 8 CF 0 H Gain Loss On Disposition Of Business And Equity Investments Net 0001757898-25-000005 Gain (Loss) on Disposition of Business And Equity Investments, Net 1
0001757898-25-000005 8 9 CF 0 H Amortization Of Inventory Fair Value Adjustments 0001757898-25-000005 Amortization of inventory fair value adjustments 0
0001757898-25-000005 8 10 CF 0 H Goodwill Impairment Loss us-gaap/2024 Goodwill, Impairment Loss 0
0001757898-25-000005 8 11 CF 0 H Other Noncash Income Expense us-gaap/2024 Other items 1
0001757898-25-000005 8 14 CF 0 H Increase Decrease In Accounts Receivable us-gaap/2024 Accounts receivable, net 1
0001757898-25-000005 8 15 CF 0 H Increase Decrease In Inventories us-gaap/2024 Inventories, net 1
0001757898-25-000005 8 16 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2024 Other current assets 1
0001757898-25-000005 8 17 CF 0 H Increase Decrease In Accounts Payable us-gaap/2024 Accounts payable 0
0001757898-25-000005 8 18 CF 0 H Increase Decrease In Accrued Liabilities us-gaap/2024 Accruals and other, net 0
0001757898-25-000005 8 19 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2024 Net cash provided by operating activities 0
0001757898-25-000005 8 21 CF 0 H Payments To Acquire Property Plant And Equipment us-gaap/2024 Purchases of property, plant, equipment, and intangibles, net 1
0001757898-25-000005 8 22 CF 0 H Proceeds From Sale Of Property Plant And Equipment us-gaap/2024 Proceeds from the sale of property, plant, equipment, and intangibles 0
0001757898-25-000005 8 23 CF 0 H Proceeds From Divestiture Of Businesses us-gaap/2024 Proceeds from Divestiture of Businesses 0
0001757898-25-000005 8 24 CF 0 H Proceeds From Sale Of Other Investments us-gaap/2024 Proceeds from Sale of Other Investments 0
0001757898-25-000005 8 25 CF 0 H Payments To Acquire Investments us-gaap/2024 Payments to Acquire Investments 1
0001757898-25-000005 8 26 CF 0 H Payments To Acquire Businesses Net Of Cash Acquired us-gaap/2024 Investments in businesses, net of cash acquired 1
0001757898-25-000005 8 27 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2024 Net cash used in investing activities 0
0001757898-25-000005 8 29 CF 0 H Repayments Of Term Loans 0001757898-25-000005 Repayments of Secured Debt 1
0001757898-25-000005 8 30 CF 0 H Payments For Repurchase Of Private Placement us-gaap/2024 Payments for Repurchase of Private Placement 1
0001757898-25-000005 8 31 CF 0 H Proceeds From Repayments Of Lines Of Credit us-gaap/2024 Proceeds Under Credit Facility, net 0
0001757898-25-000005 8 32 CF 0 H Payments Of Financing Costs us-gaap/2024 Amortization of Financing Costs 1
0001757898-25-000005 8 33 CF 0 H Payments Of Merger Related Costs Financing Activities us-gaap/2024 Payments of Merger Related Costs, Financing Activities 1
0001757898-25-000005 8 34 CF 0 H Payments For Repurchase Of Common Stock us-gaap/2024 Repurchases of ordinary shares 1
0001757898-25-000005 8 36 CF 0 H Payments To Minority Shareholders us-gaap/2024 Payments to Noncontrolling Interests 1
0001757898-25-000005 8 37 CF 0 H Proceeds From Minority Shareholders us-gaap/2024 Proceeds from Noncontrolling Interests 0
0001757898-25-000005 8 38 CF 0 H Proceeds From Payments For Other Financing Activities us-gaap/2024 Proceeds from (Payments for) Other Financing Activities 0
0001757898-25-000005 8 39 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2024 Net cash (used in) provided by financing activities 0
0001757898-25-000005 8 40 CF 0 H Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Effect of exchange rate changes on cash and cash equivalents 0
0001757898-25-000005 8 41 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2024 Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 0
0001757898-25-000005 8 42 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash and cash equivalents at beginning of period 0
0001757898-25-000005 8 43 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents us-gaap/2024 Cash and cash equivalents at end of period 0
0001757898-25-000005 9 10 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Beginning balance (in shares) 0
0001757898-25-000005 9 11 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Beginning balance 0
0001757898-25-000005 9 12 EQ 0 H Profit Loss us-gaap/2024 Net income (loss) 0
0001757898-25-000005 9 13 EQ 0 H Other Comprehensive Income Loss Net Of Tax Portion Attributable To Noncontrolling Interest us-gaap/2024 Other comprehensive income (loss) 1
0001757898-25-000005 9 14 EQ 0 H Stock Repurchased And Retired During Period Shares us-gaap/2024 Repurchases of ordinary shares (in shares) 1
0001757898-25-000005 9 15 EQ 0 H Stock Repurchased And Retired During Period Value us-gaap/2024 Repurchases of ordinary shares 1
0001757898-25-000005 9 16 EQ 0 H Stock Issued During Period Shares Employee Stock Purchase Plans us-gaap/2024 Equity compensation programs and other (in shares) 0
0001757898-25-000005 9 17 EQ 0 H Stock Issued During Period Value Employee Stock Purchase Plan us-gaap/2024 Equity compensation programs and other 0
0001757898-25-000005 9 18 EQ 0 H Dividends Common Stock Cash us-gaap/2024 Dividends, Common Stock, Cash 1
0001757898-25-000005 9 19 EQ 0 H Minority Interest Decrease From Distributions To Noncontrolling Interest Holders us-gaap/2024 Distributions to noncontrolling interest holders 1
0001757898-25-000005 9 20 EQ 0 H Noncontrolling Interest Increase From Contributions To Noncontrolling Interest Holders 0001757898-25-000005 Contributions from noncontrolling interest holders 0
0001757898-25-000005 9 21 EQ 0 H Noncontrolling Interest Decrease From Divestiture Of Joint Venture Interest 0001757898-25-000005 Divestiture of joint venture interest 1
0001757898-25-000005 9 22 EQ 0 H Increase Decrease In Noncontrolling Interests Other 0001757898-25-000005 Other changes in noncontrolling interest 1
0001757898-25-000005 9 23 EQ 0 H Stockholders Equity Including Portion Attributable To Noncontrolling Interest us-gaap/2024 Ending balance 0
0001757898-25-000005 9 24 EQ 0 H Common Stock Shares Outstanding us-gaap/2024 Ending balance (in shares) 0
0001757898-25-000005 10 1 EQ 1 H Common Stock Dividends Per Share Cash Paid us-gaap/2024 Ordinary Shares, Dividends, Per Share, Cash Paid 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.